Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftaroline fosamil vs Ceftriaxone + Vancomycin in CABP at risk for MRSA
NCT01645735Phase 4Completed
- Sponsor
- Forest Laboratories
- Start
- Oct 2012
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 4, randomised, double-blind trial of ceftaroline fosamil in community-acquired bacterial pneumonia (CAP) (2 arms), sponsored by Forest Laboratories. Primary endpoints: Clinical Response at Study Day 4 and Clinical Outcome at Test of Cure (TOC) at 3 weeks. Started Oct 2012; status: completed.
02
Drugs
ceftaroline fosamil
03
Conditions
community-acquired bacterial pneumonia (CAP)
Beyond the preview
Go deeper on NCT01645735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01645735.